Seekers come up short in hunt for meteor seen in central Victorian night sky
A group of five scientists took to paddocks near Dunolly in central Victoria on Tuesday combing the area after the meteor fell to Earth the night of August 10.
The spectacular event lit up the night sky across the region and created sonic booms that rattled houses, with reports of the rare sight flooding social media in the aftermath.
Monash University researchers formed line searches across four properties this week, ultimately coming up empty-handed.
Determined planetary geologists and the lead meteorite geochemist for the Desert Fireball Network, Rachel Kirby, said the show was not over yet.
"[We'll do some more] land searches. We're trying to tee up if we could get a drone."
The Desert Fireball Network (DFN) is made up of cameras across the country, primarily in the southern states, to track meteors as they fall.
The network includes 50 fully autonomous digital observatories that continually monitor 3 million square kilometres of the sky at night.
It was through the DFN that Dr Kirby and her team were able to pinpoint where it fell.
"Then what happens is we are able to use the data from these really specialised cameras to triangulate where it likely fell on the ground," Dr Kirby said.
"Because obviously what you see in the sky is very different from what you find on the ground.
And what happens when — or if — the researchers find the pot of gold at the end of the rainbow?
Dr Kirby said the small hunk of space rock could reveal some of the secrets of the universe.
"We will do scans of the entire rock — things like its shape and density and what it's like on the inside — and then we will break it open and sample the inside and start to really understand how and where it formed," Dr Kirby said.
Michael Brown is an observational astronomer at Monash University and was eager to join the hunt for the meteorite.
"I'm an astronomer so normally I get to see things from really far away. But, if I'm lucky, I might get to see [this one] close up," Mr Brown said.
"Often, like a lot of people, the work is analysing the data on the computer. So being out here and connecting with space and astronomy is really, really fun."
When asked what he would want the meteorite to reveal, if found and tested, Mr Brown reminisced about the early days of his career.
"I think, harking back to my research of meteorites from when I was a student, helping crack open how bits of material move around in our solar system would be particularly exciting," Mr Brown said.
Three Monash Unviersity students took up the call for adventure and joined Dr Kirby and Mr Brown in their hunt for the meteorite.
Arnika Filippi and Amelia Phillips are both science undergraduates at Monash University who said the field hunt was a valuable experience.
"Learning out in the field is so much better. It's so much easier, you really get that in-field experience," Ms Filippi said.
"They're space rocks, that's so cool," Ms Phillips said.
Joshua De Almeida is undertaking a masters in science and said the group was not deterred by the still-hidden meteorite.
"You can learn about this stuff in a book but actually finding it in the field — I have a greater appreciation for the systems that have been in place to get us here," Mr De Almeida said.
"It's so many people coming together to make all this possible. The search will continue."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

The Australian
3 hours ago
- The Australian
LTR Pharma's ED spray makes peer-reviewed journal
LTR Pharma's phase I pharmacokinetic study of nasal spray mist to treat erectile dysfunction published in leading peer-reviewed journal Publication validates five times faster onset, strengthening regulatory pathway and physician adoption LTR Pharma is targeting the US$3.7 billion ED market with SPONTAN and its other intranasal vardenafil formulation ROXUS Special Report: Results of LTR Pharma's phase I pharmacokinetic (PK) study of SPONTAN, its nasal spray mist to treat erectile dysfunction, have been published in the peer-reviewed European Journal of Pharmaceutical Sciences. The publication provides independent validation of SPONTAN – LTR Pharma's (ASX:LTP) lead intranasal vardenafil formulation for ED – including ultra-rapid onset, showing peak plasma concentrations in just 10 minutes compared with 45 minutes for conventional oral ED tablets. Mean Tmax values were 12 minutes for SPONTAN versus 56 minutes for tablets, confirming consistent rapid absorption across participants. Tmax refers to the time it takes for a drug to reach its maximum concentration (Cmax) in the bloodstream after administration. The European Journal of Pharmaceutical Sciences is a leading international peer-reviewed publication that highlights high-impact research in pharmaceutical sciences and drug delivery. Publication in the journal requires rigorous peer review by independent scientific experts and represents significant third-party validation of clinical data quality. LTR Pharma said publication in the journal adds substantial credibility to LTR's regulatory dossier as the company advances towards full commercialisation. "This peer-reviewed validation marks a transformative milestone for LTR Pharma. We now have independent scientific confirmation that our technology delivers what ED patients have been seeking for decades - true spontaneity,' executive chairman Lee Rodne said. About the PK study The randomised crossover study in 18 healthy male volunteers compared SPONTAN nasal spray (5 mg vardenafil) with oral vardenafil tablets (10 mg). Key clinical findings included: Ultra-rapid onset – SPONTAN reached peak plasma concentration (Tmax) in a median of 10 minutes versus 45 minutes for oral tablets, with mean values of 12 minutes versus 56 minutes respectively. Superior efficiency – Despite half the dose, SPONTAN achieved higher bioavailability per milligram, with dose-normalised Cmax of 2.58 ng/mL/mg versus 1.67 ng/mL/mg for oral administration. Comparable duration – Similar half-life of ~4 hours for both formulations, supporting sustained therapeutic effect. Manageable tolerability – Safety profile consistent with the PDE5 inhibitor class, with no serious adverse events reported. While the study specifically evaluated SPONTAN, the PK data support the company's broader intranasal delivery platform for vardenafil, which also includes ROXUS. Both products leverage the same rapid-onset technology, providing LTR with multiple commercial opportunities in different market segments from a single validated drug delivery platform. Targeting increased spontaneity Importantly, the publication notes that current oral PDE5 inhibitors face significant limitations, including delayed onset of 30 minutes to two hours, reduced efficacy with food intake, and the need for careful timing around sexual activity. These factors contribute to discontinuation rates of ~4% per month, with lack of spontaneity cited as a primary reason for treatment abandonment. The study authors concluded that 'intranasally delivered vardenafil is associated with more rapid onset of action with similar plasma concentrations'. They said that 'this differential pharmacokinetic profile has potentially important clinical implications given the overall safety and efficacy profile of PDE5 inhibitors in the treatment of ED, especially in men seeking sexual spontaneity'. Chief medical officer Professor Geoff Strange noted the peer-reviewed publication provided robust scientific validation of SPONTAN's 'game-changing pharmacokinetic profile'. 'The data clearly demonstrate that our intranasal delivery technology achieves the desired therapeutic levels in under 10 minutes – addressing the spontaneity challenge that drives part of the 50% of patients discontinuing oral ED treatments within their first year,' he said. 'From a clinical perspective, this represents a fundamental advancement in how PDE5 inhibitors can be administered, with the potential to significantly improve treatment adherence and patient satisfaction." SPONTAN is currently available in Australia through the Therapeutic Goods Administration Special Access Scheme, while it is targeting approval in other key markets. LTR Pharma is advancing a US Food and Drug Administration (FDA) regulatory submission via the 505(b)(2) pathway for SPONTAN approval with the US ED market valued at US$3.7 billion. The company said the journal publication strengthens its clinical evidence package for regulatory authorities. This article was developed in collaboration with LTR Pharma, a Stockhead advertiser at the time of publishing. This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.

ABC News
7 hours ago
- ABC News
Researchers scour farmland near Ballarat for meteorite after sky sightings
A group of five researchers spoke with the ABC on their hunt for a meteorite that fell to the earth on August 10th.

ABC News
7 hours ago
- ABC News
Climate change having 'irreversible' impact on Antarctica
New research, published in the journal 'Nature' this morning, shows changes in Antarctica could be irreversible - with profound consequences for Australia and the entire planet. It argues the large changes now unfolding are putting even more pressure on the global climate, sea level and ecosystems.